Back to Search Start Over

Predictors of disability worsening in clinically isolated syndrome

Authors :
Jokubaitis, VG
Spelman, T
Kalincik, T
Izquierdo, G
Grand'Maison, F
Duquette, P
Girard, M
Lugaresi, A
Grammond, P
Hupperts, R
Cabrera-Gomez, J
Oreja-Guevara, C
Boz, C
Giuliani, G
Fernandez-Bolanos, R
Iuliano, G
Lechner-Scott, J
Verheul, F
van Pesch, V
Petkovska-Boskova, T
Fiol, M
Moore, F
Cristiano, E
Alroughani, R
Bergamaschi, R
Barnett, M
Slee, M
Vella, N
Herbert, J
Shaw, C
Saladino, ML
Amato, MP
Liew, D
Paolicelli, D
Butzkueven, H
Trojano, M
Jokubaitis, VG
Spelman, T
Kalincik, T
Izquierdo, G
Grand'Maison, F
Duquette, P
Girard, M
Lugaresi, A
Grammond, P
Hupperts, R
Cabrera-Gomez, J
Oreja-Guevara, C
Boz, C
Giuliani, G
Fernandez-Bolanos, R
Iuliano, G
Lechner-Scott, J
Verheul, F
van Pesch, V
Petkovska-Boskova, T
Fiol, M
Moore, F
Cristiano, E
Alroughani, R
Bergamaschi, R
Barnett, M
Slee, M
Vella, N
Herbert, J
Shaw, C
Saladino, ML
Amato, MP
Liew, D
Paolicelli, D
Butzkueven, H
Trojano, M
Publication Year :
2015

Abstract

OBJECTIVE: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month confirmed disability worsening in clinically isolated syndrome (CIS) and early multiple sclerosis (MS). METHODS: We utilized the MSBase Incident Study (MSBasis), a prospective cohort study of outcome after CIS. Predictors of time to first 3 and 12-month confirmed expanded disability status scale worsening were analyzed using Cox proportional hazards regression. RESULTS: About 1989 patients were analyzed, the largest seen-from-onset cohort reported to-date. A total of 391 patients had a first 3-month confirmed disability worsening event, of which 307 were sustained for 12 months. Older age at CIS onset (adjusted hazard ratio: aHR 1.17, 95% 1.06, 1.30), pyramidal (aHR 1.45, 95% CI 1.13, 1.89) and ambulation (HR 1.60, 95% CI 1.09, 2.34) system dysfunction, annualized relapse rate (aHR 1.20, 95% CI 1.18, 1.22), and lower proportion of observation time on treatment were associated with 3-month confirmed worsening. Predictors of time to 12-month sustained worsening included pyramidal system dysfunction (Hazard ratio: aHR 1.38, 95% CI 1.05, 1.83), and older age at CIS onset (aHR 1.17, 95% CI 1.04, 1.31). Greater proportion of follow-up time exposed to treatment was associated with greater reductions in the rate of worsening. INTERPRETATION: This study provides class IV evidence for a strong protective effect of disease-modifying treatment to reduce disability worsening events in patients with CIS and early MS, and confirms age and pyramidal dysfunction at onset as risk factors.

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315702772
Document Type :
Electronic Resource